Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy

Author:

Ammann Eric M.1ORCID,Jones Michael P.2,Link Brian K.3,Carnahan Ryan M.1,Winiecki Scott K.4ORCID,Torner James C.1,McDowell Bradley D.5,Fireman Bruce H.6,Chrischilles Elizabeth A.15

Affiliation:

1. Department of Epidemiology and

2. Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA;

3. Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA;

4. Office of Biostatistics and Epidemiology, Center for Biologics Evaluation & Research, US Food and Drug Administration, Silver Spring, MD;

5. Population Research Core, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA; and

6. Division of Research, Kaiser Permanente Northern California, Oakland, CA

Abstract

Key Points Acute myocardial infarction and ischemic stroke risk was 3 times higher during days 0 to 1 following IVIg treatment in patients with secondary hypogammaglobulinemia. In patients treated with IVIg for 1 year, the estimated increase in the absolute risk of a severe thromboembolic event was ∼1%.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference50 articles.

1. History of immunoglobulin replacement.;Eibl;Immunol Allergy Clin North Am,2008

2. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis.;Raanani;Leuk Lymphoma,2009

3. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.;Orange;Clin Immunol,2010

4. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency.;Lee;Annu Rev Med,1997

5. FDA Medwatch Safety Alerts for Human Medical Products. Immune globulin intravenous (human) [IGIV]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154633.htm. Accessed September 19, 2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3